Please use this identifier to cite or link to this item:
Title: Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance
Authors: Armytage, Tasman ;Wight, J.;Hamad, N.;Campbell, B. A.;Ku, M.;Lee, K.;Rose, H.;Latimer, M.;Lee, H. P.;Lee, S. T.;Dickinson, M.;Khor, R.;Verner, E.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: 16-Sep-2021
Source: 52(9):1609-1623
Journal title: Internal Medicine Journal
Department: Haematology
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.15533
ISSN: 1444-0903
Publicaton type: Journal Article
Keywords: Cancer
Appears in Collections:Oncology / Cancer

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.